PFG Investments LLC Acquires 56,932 Shares of Bristol-Myers Squibb (NYSE:BMY)

PFG Investments LLC boosted its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 352.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 73,075 shares of the biopharmaceutical company's stock after purchasing an additional 56,932 shares during the quarter. PFG Investments LLC's holdings in Bristol-Myers Squibb were worth $3,963,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. McClarren Financial Advisors Inc. raised its holdings in Bristol-Myers Squibb by 532.7% during the 4th quarter. McClarren Financial Advisors Inc. now owns 1,879 shares of the biopharmaceutical company's stock valued at $96,000 after buying an additional 1,582 shares during the period. Institute for Wealth Management LLC. boosted its holdings in Bristol-Myers Squibb by 1.0% in the fourth quarter. Institute for Wealth Management LLC. now owns 30,056 shares of the biopharmaceutical company's stock worth $1,542,000 after acquiring an additional 296 shares in the last quarter. Herold Advisors Inc. boosted its holdings in Bristol-Myers Squibb by 3.2% in the third quarter. Herold Advisors Inc. now owns 33,668 shares of the biopharmaceutical company's stock worth $1,954,000 after acquiring an additional 1,051 shares in the last quarter. Kestra Private Wealth Services LLC lifted its holdings in shares of Bristol-Myers Squibb by 9.5% during the third quarter. Kestra Private Wealth Services LLC now owns 139,811 shares of the biopharmaceutical company's stock worth $8,115,000 after purchasing an additional 12,121 shares during the period. Finally, Metis Global Partners LLC boosted its position in Bristol-Myers Squibb by 14.8% in the third quarter. Metis Global Partners LLC now owns 101,772 shares of the biopharmaceutical company's stock valued at $5,907,000 after buying an additional 13,122 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on BMY. Barclays reduced their target price on Bristol-Myers Squibb from $51.00 to $43.00 and set an "equal weight" rating for the company in a research note on Friday. Wells Fargo & Company upped their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an "equal weight" rating in a report on Thursday, April 18th. StockNews.com cut Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Monday, April 15th. Redburn Atlantic lowered Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. Finally, Bank of America lowered Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and reduced their price target for the company from $68.00 to $60.00 in a research report on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $60.00.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock traded up $0.15 during trading on Friday, reaching $44.85. The company had a trading volume of 21,281,927 shares, compared to its average volume of 12,141,314. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. The firm's 50 day simple moving average is $51.03 and its two-hundred day simple moving average is $51.14. The company has a market capitalization of $90.90 billion, a PE ratio of -14.47, a PEG ratio of 16.25 and a beta of 0.39. Bristol-Myers Squibb has a one year low of $44.34 and a one year high of $69.10.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 50.04% and a negative net margin of 13.50%. Bristol-Myers Squibb's quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.05 EPS. Sell-side analysts forecast that Bristol-Myers Squibb will post 0.55 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 5.35%. Bristol-Myers Squibb's dividend payout ratio is presently -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.